IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Thyroid Cancer
Institut du Cancer de Montpellier - Val d'Aurellemonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
49 Active assets in the Thyroid Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Kineta Inc. | Phase 2 | BB |
Cyclophosphamide Anusha Kalbasi | Phase 2 | B |
Epirubicin Salubris Biotherapeutics Inc | Phase 2 | B |
Denosumab Amgen | Phase 2 | B |
[68ga]ga-nota-t4 RenJi Hospital | Phase 2/3 | CCC |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →